Physician profile
Suzanne E Savage
NPI 1316219165
$2,143.77
in general payments reported to CMS, 2019-2025
27 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $894 · 2024: $639 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.21 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.19 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $240.96 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $217.47 | 2023-2025 | |
| Amgen INC. | $213.27 | 2023-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $190.72 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.75 | 2023-2025 | Jardiance, Ofev, Tradjenta |
| Novartis Pharmaceuticals Corporation | $113.47 | 2024-2025 | |
| Astellas Pharma US INC | $86.72 | 2023-2025 | Veozah |
| Dexcom, INC. | $72.04 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $58.03 | 2023-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $55.43 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sumitomo Pharma America, INC. | $51.01 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $49.08 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $47.73 | 2023-2024 | Yupelri |
| Abbott Laboratories | $39.93 | 2023 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.10 | 2025 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $19.66 | 2024 | |
| Ardelyx, INC. | $19.58 | 2024 | Ibsrela |
| Fresenius Kabi USA, LLC | $19.44 | 2023 | Idacio |
| Azurity Pharmaceuticals, INC. | $17.94 | 2025 | Alvesco |
| Esperion Therapeutics, INC. | $17.48 | 2024 | Nexletol |
| Viatris Specialty LLC | $17.18 | 2025 | Yupelri |
| Janssen Biotech, INC. | $16.14 | 2025 | Tremfya |
| Pfizer INC. | $16.08 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2025 | Xifaxan |
| Genentech USA, INC. | $13.61 | 2025 | Actemra |
| Endogastric Solutions, INC | $8.09 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.